SCHEMBL25818580

SCHEMBL25818580

Cc1c(Br)ccc(NC(C)C(=O)O)c1[N+](=O)[O-]

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.49
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42
HCAR3 P49019 4/20 0.38
GRIN2D O15399 1/20 0.36
GRIN3B O60391 1/20 0.36
GRIN1 Q05586 1/20 0.36
GRIN2A Q12879 1/20 0.36
GRIN2B Q13224 1/20 0.36
GRIN2C Q14957 1/20 0.36
GRIN3A Q8TCU5 1/20 0.36
MAPT P10636 2/20 0.36
LMNA P02545 2/20 0.35
KDM4E B2RXH2 1/20 0.34
POLB P06746 1/20 0.34
TP53 P04637 1/20 0.34
GAA P10253 1/20 0.34
PTGER4 P35408 1/20 0.33
MMP1 P03956 1/20 0.33
MMP2 P08253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26668602 0.86 KMT2A (0.41) ALDH1A1KMT2AMEN1HCAR3GRIN2D
SCHEMBL26668820 0.83 KMT2A (0.40) ALDH1A1KMT2AMEN1HCAR3GRIN2D
SCHEMBL14764443 0.82 ALDH1A1 (0.50) ALDH1A1KMT2AMEN1HCAR3MAPT
SCHEMBL15228630 0.82 ALDH1A1 (0.50) ALDH1A1KMT2AMEN1HCAR3MAPT
SCHEMBL22032212 0.81 KMT2A (0.50) ALDH1A1KMT2AMEN1HCAR3GRIN2D
SCHEMBL16750263 0.76 MEN1 (0.43) ALDH1A1KMT2AMEN1HCAR3GRIN2D
SCHEMBL29558653 0.76 MEN1 (0.43) ALDH1A1KMT2AMEN1HCAR3GRIN2D
SCHEMBL10974753 0.74 ALDH1A1 (0.54) ALDH1A1KMT2AMEN1HCAR3MAPT
SCHEMBL31533512 0.74 MEN1 (0.44) ALDH1A1KMT2AMEN1GRIN2DGRIN3B
SCHEMBL1653800 0.74 ALDH1A1 (0.54) ALDH1A1KMT2AMEN1HCAR3MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122059929-A Quinoxaline derivatives as anticancer agents 阿斯利康(瑞典)有限公司 2026-05-19 CN disclosed
CN-122036686-A Quinoxaline derivatives as anticancer agents 阿斯利康(瑞典)有限公司 2026-05-15 CN disclosed
CN-122036687-A Quinoxaline derivatives as anticancer agents 阿斯利康(瑞典)有限公司 2026-05-15 CN disclosed
CN-122010903-A Quinoxaline derivatives as anticancer agents 阿斯利康(瑞典)有限公司 2026-05-12 CN disclosed
CN-118317793-A Methods for treating brain tumors and neuroblastomas 阿斯利康(瑞典)有限公司 2024-07-09 CN disclosed
US-11795158-B2 Chemical compounds ASTRAZENECA AB (SE) 2023-10-24 US disclosed
WO-2023118085-A1 METHODS OF TREATING BRAIN TUMOURS AND NEUROBLASTOMAS ASTRAZENECA AB (SE) 2023-06-29 WO disclosed
CN-115768760-A Quinoxaline derivatives as anti-cancer agents 阿斯利康(瑞典)有限公司 2023-03-07 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11795158-B2 Chemical compounds CYP11B2, CYP11B1, CYP4B1 ALDH1A1 123/4885KMT2A 551/4885MEN1 406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.